930.6500 13.95 (1.52%)
NSE Oct 08, 2025 15:31 PM
Volume: 92,156
 

930.65
1.52%
Karvy
In Q2FY16, total revenues of Alembic Pharmaceuticals increased by 84.4% YoY to Rs 10.1 bn (our estimates Rs 10.8 bn) compared to Rs 5.5 bn in Q2FY15, due to higher export formulations sales on account of revenues generated from Abilify opportunity.
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended